Literature DB >> 16720462

Disease manifestations and X inactivation in heterozygous females with Fabry disease.

Esther M Maier1, Stephanie Osterrieder, Catharina Whybra, Markus Ries, Andreas Gal, Michael Beck, Adelbert A Roscher, Ania C Muntau.   

Abstract

AIM: Fabry disease is an X-linked lysosomal storage disorder characterized by an accumulation of neutral glycosphingolipids in multiple organ systems caused by alpha-galactosidase A deficiency due to mutations in the GLA gene. The majority of heterozygous females show the characteristic signs and symptoms of the disease, and some of them are severely affected. The current hypothesis for the occurrence of disease manifestations in females is skewed X inactivation favouring the mutant GLA allele.
METHOD: We analyzed the patterns of X inactivation in the leukocytes of 28 biochemically and genetically characterized symptomatic Fabry disease heterozygotes and their correlation with clinical and biochemical disease expression.
RESULTS: X inactivation patterns in symptomatic females who are heterozygous for Fabry disease did not differ from those of female controls of the same age (p = 0.669). Thirteen (46%) of the 28 females with Fabry disease showed random X inactivation, ten (36%) moderate skewing, and five (18%) highly skewed X inactivation. Segregation analysis was performed in the families of six females who had highly or moderately skewed X inactivation. In four of these females, skewing favoured the wild-type GLA allele and in the other two skewing favoured the mutant allele. Patterns of X inactivation or the extent of skewing were not related to the severity of clinical manifestations or to residual enzyme activity.
CONCLUSION: In this study we provide evidence that heterozygous females with Fabry disease show random X inactivation. Our data do not support the hypothesis that the occurrence and severity of disease manifestations in the majority of Fabry heterozygotes are related to skewed X inactivation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720462     DOI: 10.1080/08035320600618809

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  28 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  X chromosome inactivation in clinical practice.

Authors:  Karen Helene Orstavik
Journal:  Hum Genet       Date:  2009-04-25       Impact factor: 4.132

3.  Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants.

Authors:  Silvia Lombardi; Mattia Ferrarese; Saverio Marchi; Paolo Pinton; Mirko Pinotti; Francesco Bernardi; Alessio Branchini
Journal:  RNA Biol       Date:  2019-10-15       Impact factor: 4.652

4.  [Anterior segment findings with far-reaching consequences].

Authors:  V Besgen; P Seipelt; Y Wenner
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

5.  Skewed X inactivation in Lesch-Nyhan disease carrier females.

Authors:  Rosa J Torres; Juan G Puig
Journal:  J Hum Genet       Date:  2017-09-14       Impact factor: 3.172

6.  Early cardiovascular remodelling in Fabry disease.

Authors:  Luca Costanzo; Sergio Buccheri; Piera Capranzano; Luigi Di Pino; Giuseppina Curatolo; Margherita Rodolico; Stefano Leggio; Anita Blundo; Corrado Tamburino; Ines Monte
Journal:  J Inherit Metab Dis       Date:  2013-04-25       Impact factor: 4.982

Review 7.  Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.

Authors:  Louise L C Pinto; Taiane A Vieira; Roberto Giugliani; Ida V D Schwartz
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

8.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert Dobrovolny; Ai-Chu Huang; Hui-Ying Yeh; May-Chin Chao; Shio-Jean Lin; Teruo Kitagawa; Robert J Desnick; Li-Wen Hsu
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

9.  Genetic polymorphisms of vitamin D receptor (VDR) in Fabry disease.

Authors:  Michael Teitcher; Sarah Weinerman; Catharina Whybra; Michael Beck; Nir Sharon; Deborah Elstein; Gheona Altarescu
Journal:  Genetica       Date:  2008-02-16       Impact factor: 1.082

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.